Genetic moderators of naltrexone's effects on alcohol cue reactivity

Alcoholism: Clinical and Experimental Research

Volumn 30, Issue 8, 2006, Pages 1288-1296

  McGeary, John E ^a,b   Monti, Peter M ^a,b   Rohsenow, Damaris J ^a,b   Tidey, Jennifer ^a   Swift, Robert ^a,b   Miranda Jr , Robert ^a  

^a BROWN UNIVERSITY   (United States)

^b PROVIDENCE VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Cue Reactivity; DRD4; Naltrexone; OPRM1; Urge to Drink

Indexed keywords

ASPARAGINE; ASPARTIC ACID; DOPAMINE 4 RECEPTOR; NALTREXONE; PLACEBO;

ADULT; ALCOHOL CONSUMPTION; ALCOHOLISM; AMINO ACID SUBSTITUTION; ARTICLE; ASSOCIATION; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRINKING BEHAVIOR; DRUG EFFECT; FEMALE; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; PHARMACOGENETICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SAMPLE SIZE; SEX RATIO; SINGLE NUCLEOTIDE POLYMORPHISM; TANDEM REPEAT; WITHDRAWAL SYNDROME;

ADOLESCENT; ADULT; ALCOHOL DRINKING; ALCOHOLISM; ANALYSIS OF VARIANCE; CHI-SQUARE DISTRIBUTION; CUES; ETHANOL; FEMALE; GENOTYPE; HUMANS; MALE; NALTREXONE; RECEPTORS, DOPAMINE D4; RECEPTORS, OPIOID, MU; VARIATION (GENETICS);

EID: 33746349505     PISSN: 01456008     EISSN: 15300277     Source Type: Journal    
DOI: 10.1111/j.1530-0277.2006.00156.x     Document Type: Article

References (63)

1. Anton RF (1999) What is craving? Models and implications for treatment. Alcohol Res Health 23:165-173.
2. Arias A, Feinn R, Kranzler HR (2005) Association of an Asn40Asp (A118G) polymorphism in the mu-opioid receptor gene with substance dependence: a meta-analysis. Drug Alcohol Depend Dec 29 [Epub ahead of print].
3. Asghari V, Sanyal S, Buchwaldt S, Paterson A, Jovanovic V, Van Tol HH (1995) Modulation of intracellular cyclic AMP levels by different human dopamine D4 receptor variants. J Neurochem 65:1157-1165.
4. Bart G, Kreek MJ, Ott J, LaForge KS, Proudnikov D, Pollak L, Heilig M (2005) Increased attributable risk related to a functional mu-opioid receptor gene polymorphism in association with alcohol dependence in central Sweden. Neuropsychopharmacology 30:417-422.
5. Befort K, Filliol D, Decaillot FM, Gaveriaux-Ruff C, Hoehe MR, Kieffer BL (2001) A single nucleotide polymorphic mutation in the human mu-opioid receptor severely impairs receptor signaling. J Biol Chem 276:3130-3137.
6. Bergen AW, Kokoszka J, Peterson R, Long JC, Virkkunen M, Linnoila M, Goldman D (1997) Mu opioid receptor gene variants: lack of association with alcohol dependence. Mol Psychiatry 2:490-494.
7. Beyer A, Koch T, Schroder H, Schulz S, Hollt V (2004) Effect of the A118G polymorphism on binding affinity, potency and agonist-mediated endocytosis, desensitization, and resensitization of the human mu-opioid receptor. J Neurochem 89:553-560.
8. Bond C, LaForge KS, Tian M, Melia D, Zhang S, Borg L, Gong J, Schluger J, Strong JA, Leal SM, Tischfield JA, Kreek MJ, Yu L (1998) Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction. Proc Natl Acad Sci U S A 95:9608-9613.
9. Bottlender M, Soyka M (2004) Impact of craving on alcohol relapse during, and 12 months following, outpatient treatment. Alcohol Alcohol 39:357-361.
10. Cohen (1988) Statistical Power Analysis for the Behavioral Sciences. Hillsdale (NJ): Lawrence Erlbaum Associates Inc.
11. Colby SM, Rohsenow DJ, Monti PM, Gwaltney CJ, Gulliver SB, Abrams DB, Niaura RS, Sirota AD (2004) Effects of tobacco deprivation on alcohol cue reactivity and drinking among young adults. Addict Behav 29:879-892.
12. Cooney NL, Litt MD, Morse PA, Bauer LO, Gaupp L (1997) Alcohol cue reactivity, negative-mood reactivity, and relapse in treated alcoholic men. J Abnorm Psychol 106:243-250.
13. Curtin JJ, Barnett NP, Colby SM, Rohsenow DJ, Monti PM (2005) Cue-reactivity in adolescents: measurement of separate approach and avoidance reactions. J Stud Alcohol 66:332-343.
14. Davidson D, Palfai T, Bird C, Swift R (1999) Effects of naltrexone on alcohol self-administration in heavy drinkers. Alcohol Clin Exp Res 23:195-203.
15. Davidson D, Saha C, Scifres S, Fyffe J, O'Connor S, Selzer C (2004) Naltrexone and brief counseling to reduce heavy drinking in hazardous drinkers. Addict Behav 29:1253-1258.
16. Davidson D, Swift R, Fitz E (1996) Naltrexone increases the latency to drink alcohol in social drinkers. Alcohol Clin Exp Res 20:732-739.
17. DeHaven-Hudkins DL, Brostrom PA, Allen JT, Lesko LJ, Ferkany JW, Kaplita PV, Mavunkel BJ, Rzeszotarski WJ, Steranka LR (1990) Pharmacologic profile of NPC 168 (naltrexone phenyl oxime), a novel compound with activity at opioid receptors. Pharmacol Biochem Behav 37:497-504.
18. Drobes DJ, Anton RF, Thomas SE, Voronin K (2004) Effects of naltrexone and nalmefene on subjective response to alcohol among non-treatment-seeking alcoholics and social drinkers. Alcohol Clin Exp Res 28:1362-70.
19. Farren CK, O'Malley S, Grebski G, Maniar S, Porter M, Kreek MJ (1999) Variable dose naltrexone-induced hypothalamic-pituitary-adrenal stimulation in abstinent alcoholics: a preliminary study. Alcohol Clin Exp Res 23:502-508.
20. First MB, Spitzer RL, Gibbon M, Williams JBW, Davies M, Borus J, Howes MJ, Kane J, Pope HG, Rounsaville B (1995) The structured clinical interview for DSM-III-R personality disorders (SCID-II). Part II: multi-site test-retest reliability study. J Personal Disord 9:92-104.
21. Flannery BA, Allen JP, Pettinati HM, Rohsenow DJ, Cisler RA, Litten RZ (2002) Using acquired knowledge and new technologies in alcoholism treatment trials. Alcohol Clin Exp Res 26:423-429.
22. Flannery BA, Poole SA, Gallop RJ, Volpicelli JR (2003) Alcohol craving predicts drinking during treatment: an analysis of three assessment instruments. J Stud Alcohol 64:120-126.
23. Freeman B, Powell J, Ball D, Hill L, Craig I, Plomin R (1997) DNA by mail: an inexpensive and noninvasive method for collecting DNA samples from widely dispersed populations. Behav Genet 27:251-257.
24. Gelernter J, Kranzler H, Cubells J (1999) Genetics of two mu opioid receptor gene (OPRM1) exon I polymorphisms: population studies, and allele frequencies in alcohol- and drug-dependent subjects. Mol Psychiatry 4:476-483.
25. Hernandez-Avila CA, Wand G, Luo X, Gelernter J, Kranzler HR (2003) Association between the cortisol response to opioid blockade and the Asn40Asp polymorphism at the mu-opioid receptor locus (OPRM1). Am J Med Genet 118B:60-65.
26. Hersh D, Bauer LO, Kranzler HR (1995) Carbamazepine and cocaine-cue reactivity. Drug Alcohol Depend 39:213-221.
27. Hutchison KE, McGeary J, Smolen A, Bryan A, Swift RM (2002) The DRD4 VNTR polymorphism moderates craving after alcohol consumption. Health Psychol 21:139-146.
28. Hutchison KE, Wooden A, Swift RM, Smolen A, McGeary J, Adler L, Paris L (2003) Olanzapine reduces craving for alcohol: a DRD4 VNTR polymorphism by pharmacotherapy interaction. Neuropsychopharmacology 28:1882-1888.
29. Inoue H (2000) Effects of naltrexone on the accumulation of L-3,4-dihydroxyphenylalanine and 5-hydroxy-L-tryptophan and on the firing rate induced by acute ethanol administration. Eur J Pharmacol 406:375-380.
30. King AC, Volpicelli JR, Frazer A, O'Brien CP (1997) Effect of naltrexone on subjective alcohol response in subjects at high and low risk for future alcohol dependence. Psychopharmacology 129:15-22.
31. Kozlowski LT, Mann RE, Wilkinson DA, Poulos CX (1989) "Cravings" are ambiguous: ask about urges or desires. Addict Behav 14:443-445.
32. Lench N, Stanier P, Williamson R (1988) Simple non-invasive method to obtain DNA for gene analysis. Lancet 18:1356-1358.
33. Lesscher HM, Bailey A, Burbach JP, Van Ree JM, Kitchen I, Gerrits MA (2003) Receptor-selective changes in mu-, delta- and kappa-opioid receptors after chronic naltrexone treatment in mice. Eur J Neurosci 17:1006-1012.
34. Lichter JB, Barr CL, Kennedy JL, Van Tol HH, Kidd KK, Livak KJ (1993) A hypervariable segment in the human dopamine receptor D4 (DRD4) gene. Hum Mol Genet 2:767-773.
35. Mann RE, Sobell LC, Sobell MB, Pavan D (1985) Reliability of a family tree questionnaire for assessing family history of alcohol problems. Drug Alcohol Depend 15:61-67.
36. McCaul ME (1998) Substance abuse vulnerability in offspring of alcohol and drug abusers. NIDA Res Monogr 169:188-208.
37. McCaul ME, Monti PM (2003) Research priorities for alcoholism treatment. Recent Dev Alcohol 16:405-414.
38. Monterosso JR, Flannery BA, Pettinati HM, Oslin DW, Rukstalis M, O'Brien CP, Volpicelli JR (2001) Predicting treatment response to naltrexone: the influence of craving and family history. Am J Addict 10:258-268.
39. Monti PM, Binkoff JA, Abrams DB, Zwick WR, Nirenberg TD, Liepman MR (1987) Reactivity of alcoholics and nonalcoholics to drinking cues. J Abnorm Psychol 96:122-126.
40. Monti PM, Rohsenow DJ, Hutchison KE (2000) Toward bridging the gap between biological, psychobiological and psychosocial models of alcohol craving. Addiction 95 (Suppl. 2): 229S-236S.
41. Monti PM, Rohsenow DJ, Hutchison KE, Swift RM, Mueller TI, Colby SM, Brown RA, Gulliver SB, Gordon A, Abrams DB (1999) Naltrexone's effect on cue-elicited craving among alcoholics in treatment. Alcohol Clin Exp Res 23:1386-1394.
42. Monti PM, Rohsenow DJ, Swift RM, Gulliver SB, Colby SM, Mueller TI, Brown RA, Gordon A, Abrams DB, Niaura RS, Asher MK (2001) Naltrexone and cue exposure with coping and communication skills training for alcoholics: treatment process and 1-year outcomes. Alcohol Clin Exp Res 25:1634-1647.
43. Monti PM, Kadden RM, Rohsenow DJ, Cooney NL, Abrams DB (2002) Treating Alcohol Dependence: A Coping Skills Training Guide, 2nd ed. Guilford Press, New York.
44. Na C, Lee YS (2002) Alcohol urge and plasma beta-endorphin change after alcohol challenge with naltrexone pretreatment in social drinkers. Prog Neuropsychopharmacol Biol Psychiatry 26:663-670.
45. Niaura RS, Rohsenow DJ, Binkoff JA, Monti PM, Pedraza M, Abrams DB (1988) Relevance of cue reactivity to understanding alcohol and smoking relapse. J Abnorm Psychol 97:133-152.
46. O'Malley SS, Krishnan-Sarin S, Farren C, Sinha R, Kreek MJ (2002) Naltrexone decreases craving and alcohol self-administration in alcohol-dependent subjects and activates the hypothalamo-pituitary- adrenocortical axis. Psychopharmacology 160:19-29. Epub 2002 January 22.
47. Oslin DW, Berrettini W, Kranzler HR, Pettinati H, Gelernter J, Volpicelli JR, O'Brien CP (2003) A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. Neuropsychopharmacology 28:1546-1552.
48. Pickens RW, Johanson CE (1992) Craving: consensus of status and agenda for future research. Drug Alcohol Depend 30:127-131.
49. Ray LA, Hutchison KE (2004) A polymorphism of the mu-opioid receptor gene (OPRM1) and sensitivity to the effects of alcohol in humans. Alcohol Clin Exp Res 28:1789-1795.
50. Robbins SJ, Ehrman RN, Childress AR, O'Brien CP (1992) Using cue reactivity to screen medications for cocaine abuse: a test of amantadine hydrochloride. Addict Behav 17:491-499.
51. Rohsenow DJ (2004) What place does naltrexone have in the treatment of alcoholism? CNS Drugs 18:547-560.
52. Rohsenow DJ, Monti PM (1999) Does urge to drink predict relapse after treatment. Alcohol Res Health 23:225-232.
53. Rohsenow DJ, Monti PM, Hutchison KE, Swift RM, Colby SM, Kaplan GB (2000) Naltrexone's effects on reactivity to alcohol cues among alcoholic men. J Abnorm Psychol 109:738-742.
54. Rohsenow DJ, Monti PM, Rubonis AV, Sirota AD, Niaura RS, Colby SM, Wunschel SM, Abrams DB (1994) Cue reactivity as a predictor of drinking among male alcoholics. J Consult Clin Psychol 62:620-626.
55. Sander T, Harms H, Dufeu P, Kuhn S, Rommelspacher H, Schmidt LG (1997) Dopamine D4 receptor exon III alleles and variation of novelty seeking in alcoholics. Am J Med Genet 74:483-487.
56. Smolka M, Sander T, Schmidt LG, Samochowiec J, Rommelspacher H, Gscheidel N, Wendel B, Hoehe MR (1999) Mu-opioid receptor variants and dopaminergic sensitivity in alcohol withdrawal. Psychoneuroendocrinology 24:629-638.
57. Sobell LC, Maisto SA, Sobell MB, Cooper AM (1979) Reliability of alcohol abusers' self-reports of drinking behavior. Behav Res Ther 17:157-60.
58. Swift RM (1999) Medications and alcohol craving. Alcohol Res Health 23:207-213.
59. Swift RM, Whelihan W, Kuznetsov O, Buongiorno G, Hsuing H (1994) Naltrexone-induced alterations in human ethanol intoxication. Am J Psychiatry 151:1463-1467.
60. Tiffany ST (1990) A cognitive model of drug urges and drug-use behavior: role of automatic and nonautomatic processes. Psychol Rev 97:147-168.
61. Volpicelli JR, Rhines KC, Rhines JS, Volpicelli LA, Alterman AI, O'Brien CP (1997) Naltrexone and alcohol dependence. Role of subject compliance. Arch Gen Psychiatry 54:737-742.
62. Wand GS, McCaul M, Yang X, Reynolds J, Gotjen D, Lee S, Ali A (2002) The mu-opioid receptor gene polymorphism (A118G) alters HPA axis activation induced by opioid receptor blockade. Neuropsychopharmacology 26:106-114.
63. Wise RA (1980) Actions of drugs of abuse on the brain reward systems. Pharmacol Biochem Behav 13 (Suppl. 1): 213-223.